Manage your formulary budget
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Proactively manage your pharmacy inventory
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Retroviral protease inhibiting compounds|
|Abstract:||A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.|
|Inventor(s):||Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing L. (Gurnee, IL), Zhao; Chen (Gurnee, IL), Sowin; Thomas J. (Grayslake, IL), Reno; Daniel S. (Kenosha, IL), Allen; Michael S. (Silver Lake, WI), Copper; Arthur J. (Lake Villa, IL), Tien; Jien-Heh J. (Libertyville, IL)|
|Assignee:||Abbott Laboratories (Abbott Park, IL)|
|Filing Date:||Apr 05, 1995|
|Claims:||1. A process for the preparation of a compound of the formula: ##STR18## wherein R.sub.4 and R.sub.4a are independently selected from phenyl, thiazolyl and oxazolyl wherein the phenyl, thiazolyl or oxazolyl ring is unsubstituted or substituted with a substituent selected from |
(i) halo, (ii) loweralkyl, (iii) hydroxy, (iv) alkoxy and (v) thioalkoxy;
R.sub.6 is hydrogen or loweralkyl; and
R.sub.7 is thiazolyl, oxazolyl, isoxazolyl or isothiazolyl wherein the thiazolyl, oxazolyl, isoxazolyl or isothiazolyl ring is unsubstituted or substituted with loweralkyl; or an acid addition salt thereof, comprising reacting a compound of the formula: ##STR19## wherein R.sub.4 and R.sub.4a are defined as above with a compound of the formula (R.sub.6)(R.sub.7)CHOC(O)OL wherein L is an activating group for the acylation reaction and wherein R.sub.6 and R.sub.7 are defined as above, followed by N-deprotection.
2. The process of claim 1 wherein R.sub.4 and R.sub.4a are phenyl and L is p-nitrophenyl.
3. A process for the preparation of (2S,3S,5S)-5-Amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl- 3-hydroxyhexane or an acid addition salt thereof, comprising reacting (2S,3S,5S)-5-(t-Butyloxycarbonylamino)-2(N-((5-thiazolyl)methoxycarbonyl)a mino)-1,6-diphenyl-3-hydroxyhexane with 5-(p-nitrophenyloxycarbonyloxymethyl)thiazole, followed by N-deprotection.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.